Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Ameliorative Effects of Atorvastatin on Bleomycin-Induced Pulmonary Fibrosis in Rats

Ali Asghar Hemmeti 1 , 2 , Mohammad Rahim Zerafatfard 1 , Mehdi Goudarzi 1 , Mohammad Javad Khodayar 1 , 3 , * , Anahita Rezaie 4 , Mohammad Reza Rashidi Nooshabadi 1 and Milad Kiani 1
Authors Information
1 Department of Pharmacology and Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
2 Physiology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
3 Toxicology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
4 Department of Pathobiology, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: November 2016, 11 (4); e13370
  • Published Online: September 17, 2016
  • Article Type: Research Article
  • Received: September 9, 2013
  • Revised: May 24, 2016
  • Accepted: August 17, 2016
  • DOI: 10.17795/jjnpp-13370

To Cite: Hemmeti A A, Zerafatfard M R, Goudarzi M, Khodayar M J, Rezaie A, et al. Ameliorative Effects of Atorvastatin on Bleomycin-Induced Pulmonary Fibrosis in Rats, Jundishapur J Nat Pharm Prod. 2016 ; 11(4):e13370. doi: 10.17795/jjnpp-13370.

Copyright © 2016, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012; 21(126): 355-61[DOI][PubMed]
  • 2. Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet. 2012; 380(9842): 680-8[DOI][PubMed]
  • 3. Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol. 2014; 9: 157-79[DOI][PubMed]
  • 4. Grande NR, Peao MN, de Sa C. M. , Aguas AP. Lung fibrosis induced by bleomycin: structural changes and overview of recent advances. Scanning Microsc. 1998; 12(3): 487-94
  • 5. B. Moore B , Lawson WE, Oury TD, Sisson TH, Raghavendran K, Hogaboam CM. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol. 2013; 49(2): 167-79[DOI][PubMed]
  • 6. Javadi I, Rashidi Nooshabadi M, Goudarzi M, Roudbari R. Protective Effects of Celery (Apium graveloens) Seed Extract on Bleomycin-Induced Pulmonary Fibrosis in Rats. J Bbol Uni Med Sci. 2015; 17(1): 70-6
  • 7. Ebrahimi Naghani E, Javadi I, Rashidinooshabadi M, Godarzi M, Houshmand G. Protective Effects of Hydroalcoholic Extract of Hypericum Perforatum Against Bleomycin-Induced Pulmonary Fibrosis in Rats. J Babol Uni Med Sci. 2016; 18(1): 44-51
  • 8. Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014; 88: 3-11[DOI][PubMed]
  • 9. Atorvastatin F. Statins: HMG-CoA Reductase Inhibitors. 2013;
  • 10. Node K, Liao JK. Pleiotropic effects of HMG-CoA reductase. HMG-CoA Reductase Inhibit. 2012; : 81
  • 11. Murrow JR, Sher S, Ali S, Uphoff I, Patel R, Porkert M, et al. The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin. J Clin Lipidol. 2012; 6(1): 42-9[DOI][PubMed]
  • 12. Sozer V. Ameliorative effect of statin therapy on oxidative damage in heart tissue of hypercholesterolemic rabbits. Fundam Clin Pharmacol. 2015; 29(6): 558-66[DOI][PubMed]
  • 13. Margaritis M, Channon KM, Antoniades C. Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. Antioxid Redox Signal. 2014; 20(8): 1198-215[DOI][PubMed]
  • 14. Subramanian S, Emami H, Vucic E, Singh P, Vijayakumar J, Fifer KM, et al. High-dose atorvastatin reduces periodontal inflammation: a novel pleiotropic effect of statins. J Am Coll Cardiol. 2013; 62(25): 2382-91[DOI][PubMed]
  • 15. Ortego M, Bustos C, Hernandez-Presa MA, Tu-on J, Diaz C, Hernandez G. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999; 147(2): 253-61[DOI]
  • 16. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001; 59(3): 646-54[PubMed]
  • 17. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 2001; 154(1): 87-96[PubMed]
  • 18. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003; 108(4): 426-31[DOI][PubMed]
  • 19. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis. 1998; 138(2): 271-80[DOI]
  • 20. Zhu B, Ma AQ, Yang L, Dang XM. Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway. Int J Mol Sci. 2013; 14(12): 24476-91[DOI][PubMed]
  • 21. Khodayar MJ, Kiani M, Hemmati AA, Rezaie A, Zerafatfard MR, Rashidi Nooshabadi MR, et al. The preventive effect of atorvastatin on paraquat-induced pulmonary fibrosis in the rats. Adv Pharm Bull. 2014; 4(4): 345-9[DOI][PubMed]
  • 22. Hemmati AA, Mikaili P, Khodayar MJ, Ghafurian M, Rashidi I. The protective effect of Cetirizine against Bleomycine induced pulmonary fibrosis in rats. Pak J Med Sci. 2008; 24(6): 813-20
  • 23. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988; 41(4): 467-70[PubMed]
  • 24. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem. 1996; 29(3): 225-9[PubMed]
  • 25. Javad-Mousavi SA, Hemmati AA, Mehrzadi S, Hosseinzadeh A, Houshmand G, Rashidi Nooshabadi MR, et al. Protective effect of Berberis vulgaris fruit extract against Paraquat-induced pulmonary fibrosis in rats. Biomed Pharmacother. 2016; 81: 329-36[DOI][PubMed]
  • 26. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978; 52: 302-10[PubMed]
  • 27. Kiener PA, Davis PM, Murray JL, Youssef S, Rankin BM, Kowala M. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol. 2001; 1(1): 105-18[DOI]
  • 28. Singh U, Devaraj S, Jialal I, Siegel D. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol. 2008; 102(3): 321-5[DOI][PubMed]
  • 29. Costabel U, King TE. International consensus statement on idiopathic pulmonary fibrosis. Eur Respir J. 2001; 17(2): 163-7[PubMed]
  • 30. Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol. 1991; 65(2): 81-94[PubMed]
  • 31. Sogut S, Ozyurt H, Armutcu F, Kart L, Iraz M, Akyol O, et al. Erdosteine prevents bleomycin-induced pulmonary fibrosis in rats. Eur J Pharmacol. 2004; 494(2-3): 213-20[DOI][PubMed]
  • 32. Balakumar P, Mahadevan N. Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword? Br J Pharmacol. 2012; 165(2): 373-9[DOI][PubMed]
  • 33. Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, et al. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res. 2006; 98(3): 361-9[DOI][PubMed]
  • 34. Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther. 2006; 110(3): 371-85[DOI][PubMed]
  • 35. Mansure J, Nassim R, Kassouf W. Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target in cancer. Cellular Genetic Practices Translational Med. 2011; 8(7): 169-95
  • 36. Zheng X, Cui XX, Avila GE, Huang MT, Liu Y, Patel J, et al. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res. 2007; 13(18 Pt 1): 5480-7[DOI][PubMed]
  • 37. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax. 2006; 61(8): 729-34[DOI][PubMed]
  • 38. Costa S, Reina-Couto M, Albino-Teixeira A, Sousa T. Statins and oxidative stress in chronic heart failure. Revista portuguesa de cardiologia: orgao oficial da Sociedade Portuguesa de Cardiologia. Portuguese J Cardiol. 2016;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments